CIS
发表于 2025-3-25 07:12:17
http://reply.papertrans.cn/84/8308/830795/830795_21.png
Modicum
发表于 2025-3-25 10:13:18
http://reply.papertrans.cn/84/8308/830795/830795_22.png
antenna
发表于 2025-3-25 12:13:25
New Agents and New Insights for Thrombolytic Therapy in Acute Myocardial Infarction: Focus on Anistr testing. Prourokinase is a fibrin-selective precursor form of urokinase undergoing initial trials both as a single agent and in combinations with urokinase and TPA. These agents expand the spectrum of thrombolytic options and may begin to impact clinical therapy in the near future.
折磨
发表于 2025-3-25 16:47:27
http://reply.papertrans.cn/84/8308/830795/830795_24.png
世俗
发表于 2025-3-25 21:05:32
http://reply.papertrans.cn/84/8308/830795/830795_25.png
canonical
发表于 2025-3-26 03:14:47
http://reply.papertrans.cn/84/8308/830795/830795_26.png
dapper
发表于 2025-3-26 06:34:26
The Relative Benefit and Risks of Intravenous Streptokinase and Tissue Plasminogen Activator in Acutal infarction, Separate from the generic questions of patient selection criteria has been a sometimes acrimonious commercial issue-tinged debate concerning the relative risks and benefits to be expected following the use of one or the other of these two agents. Arguments center on questions of relat
Immortal
发表于 2025-3-26 09:55:06
New Agents and New Insights for Thrombolytic Therapy in Acute Myocardial Infarction: Focus on Anistr anisoylated lys-plasminogen and streptokinase which is injected in a dose of 30 U over 2–5 min. Reperfusion rates of 60+10% and patency rates of 70–75% have been observed when it is given in <4 h. Mortality was reduced 48% after anistreplase in one study (AIMS). Intravenous urokinase has yielded re
萤火虫
发表于 2025-3-26 13:34:14
http://reply.papertrans.cn/84/8308/830795/830795_29.png
钩针织物
发表于 2025-3-26 20:16:01
http://reply.papertrans.cn/84/8308/830795/830795_30.png